Tuesday, 20 November 2018 04:38 GMT
img

Acacia Pharma Group plc - PDMR DEALING/EXERCISE OF SHARE OPTIONS



(MENAFN - GlobeNewsWire - Nasdaq) itemprop="articleBody">TOTAL VOTING RIGHTS

Cambridge, UK and Indianapolis, US - 6 November 2018: Acacia Pharma Group plc ( the "Company), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that it has received notice of exercise of options under the Company's Enterprise Management Incentive Share Option Plan from Dr Julian Gilbert (Chief Executive Officer and PDMR) to subscribe for 139,370 Ordinary Shares of £0.02 each in the Company and from Dr Gabriel Fox (Chief Medical Officer and PDMR) to subscribe for 70,774 Ordinary Shares of £0.02 each in the Company (together the 210,144 "New Ordinary Shares") at an exercise price of £0.38 per share. In both cases the options were exercised on 5 November, immediately before the end of the 10 year term of the options, which if unexercised by that date, would otherwise lapse.

                          Â
Following the exercise of these options, Dr Gilbert holds 840,955 Ordinary Shares, representing approximately 1.58% of the Company's enlarged issued share capital. Dr Fox holds 323,478 Ordinary Shares, representing approximately 0.61% of the Company's enlarged issued share capital.Â

Application has been made to Euronext Brussels for the admission of the New Ordinary Shares to trading on Euronext Brussels ("Admission").  The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue.
                                   Â
Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 53,329,205 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 53,329,205.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr Julian Gilbert 2 Reason for the notification a) Position/status Chief Executive Officer/PDMR b) Initial notification/ Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Acacia Pharma Group plc b) LEI 213800SLDKXWKT6E3381 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument

Â

Identification code Ordinary Shares of £0.02 each

Â

Â

Â

GB00BYWF9Y76 b) Nature of the transaction Share options exercise c) Price(s) and volume(s) 139,370 Ordinary Shares of £0.02 at a price of £0.38 per share d) Aggregated information
- Aggregated volume
- Price

 N/A e) Date of the transaction  5 November 2018

 f) Place of the transaction Euronext Brussels (XBRU)


1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr Gabriel Fox 2 Reason for the notification a) Position/status Chief Medical Officer/PDMR b) Initial notification/ Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Acacia Pharma Group plc b) LEI 213800SLDKXWKT6E3381 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument

Â

Identification code Ordinary Shares of £0.02 each

Â

Â

Â

GB00BYWF9Y76 b) Nature of the transaction Share options exercise c) Price(s) and volume(s) 70,774 Ordinary Shares of £0.02 at a price of £0.38 per share d) Aggregated information
- Aggregated volume
- Price

 N/A e) Date of the transaction  5 November 2018

 f) Place of the transaction Euronext Brussels (XBRU)

ContactsÂ

Acacia Pharma Group plc
Julian Gilbert, CEO
Christine Soden, CFO +44 1223 919760 Citigate Dewe RogersonÂ
Mark Swallow, Shabnam Bashir, David Dible +44 20 7638 9571

Â

MENAFN0611201800703653ID1097664905


Acacia Pharma Group plc - PDMR DEALING/EXERCISE OF SHARE OPTIONS

  Most popular stories  

Day | Week | Month